Access to Medicines
More about the ongoing talks at WTO to increase access to essential medicines, especially in developing countries.
Please find all related articles below.
October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1).
Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
Health is a fundamental universal right and access to medicines is part of it. The EU and its Member States are committed to universal and equitable access to healthcare. Nevertheless, millions of European patients suffer from the lack of affordability of many life-saving medicines across Europe.
Download the event’s invitation
* See the event’s poster
An event under the auspices of MEPs Nessa CHILDERS (S&D, IE), Beatriz BECERRA BASTERRECHEA (ALDE, ES), Kostas (...)
October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4).
“I would like to applaud President-elect (...)
8th October 2014, Brussels - With regard to the planned transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (#Pharma4Health campaign), we would like to inform you that the Conference of the Presidents of the European Parliament (composed of the President of the European Parliament, Martin Schulz and the leaders of the political groups) will meet tomorrow on 9th October (Thursday).
Dear EPHA Members,
We would like to (...)
“Placing pharma policy in DG Enterprise was justified. It has traditionally been in DG Enterprise, but was moved to DG Sanco and has once again been instated as an Enterprise competence” said during her hearing Commissioner-designate Elzbieta Bienkowska.
By Dorota Sienkiewicz,Health Equity and Policy Coherence Coordinator, and Martyna Giedrojć, EPHA Policy Officer for Health Systems
The pharmaceutical industry is the biggest sector in the world. In terms of production, (...)
Elżbieta Bieńkowska (born on 4 February 1964 in Katowice, Poland) became the Minister of Regional Development in the Cabinet of the Prime Minister Donald Tusk between 2007 and 2013 in Poland. She was then appointed a Deputy Prime Minister and carried out her mandate at the Ministry of Infrastructure and Development. In 2014 she has been nominated by the Polish government for European Commissioner who has received the Internal Market, Industry, Entrepreneurship and SMEs portfolio (...)
From 1 November 2014, Cecilia Malmström will take office as the new Commissioner for Trade, under the Juncker Commission. The appointment of Swedish native Ms. Malmstrom implies that the President-elect of the European Commission, Jean-Claude Juncker, would like to further promote discussion with the U.S. on the much debated Transatlantic Trade and Investment Partnership (TTIP).
By Leonardo Palumbo, EPHA Policy Coordinator for EU Affairs and Arthur Matthews, Policy Assistant
Frans Timmermans has been officially designated to be one of the six Vice-Presidents and the First Vice-President in charge of Better Regulation, Inter-Institutional Relations, the Rule of Law and the Charter of Fundamental Rights – a newly installed Directorate General.
By Dorota Sienkiewicz, EPHA Health Equity and Policy Coherence Coordinator
Putting in place this brand new DG reflects the EU’s new strategy to focus on areas where it can make a difference (in its own (...)
After months of inaction and neglect from the international community, the Ebola epidemic in west Africa has now spiralled utterly out of control. Today, the virus is a threat not only to the countries where the outbreak has overwhelmed the capacity of national health systems, but also to the entire world.
We urge our governments to mobilise all possible resources to assist west Africa in controlling this horrific epidemic. Based on our (...)
A study in Germany, France and the Netherlands highlights an alarming trend: the majority of medicines granted marketing authorisation has no added therapeutic value (ATV) compared to medicines already on the market. In some cases the new medicine even did more harm than good. These are the results of a research conducted by Wemos and EPHA. The figures are based on evaluations of several international drug bulletins.
1st October 2014, Brussels - The French drug bulletin La Revue Prescrire (...)